

**Fra:** EuroSIDA [eurosida@cphiv.dk]  
**Sendt:** 10. oktober 2013 10:55  
**Til:** CHIP internal  
**Emne:** EuroSIDA Newsletter October 2013

Se dette nyhedsbrev i en browser

# EuroSIDA Newsletter

## October 2013



### **EuroSIDA at EACS, Brussels, 16-19 October 2013**

It is a pleasure to inform you that EuroSIDA – as usual – is well profiled at the EACS conference. This time, a total of 10 abstracts will be presented in Brussels – 4 of these are orals and 6 as posters.

We kindly invite all EuroSIDA investigators to the **EuroSIDA Investigator meeting: 17 October at 12:30-13:30, room 314+316** (lunch will be served)

We hope to see many of you there for an update of all the ongoing activities within EuroSIDA. Please confirm your participation to Charlotte Matthews [eurosida@cphiv.dk](mailto:eurosida@cphiv.dk)

#### **Oral presentations:**

**Prevalence of Detected Drug Resistance across Different Regions of Europe: Data from EuroSIDA 1997-2012**, A. Schultze (EuroSIDA in EuroCOORD)

*Thursday 17. October at 10.30-12:30/Gold Hall*

**The Spectrum of clinical Disease in HIV-positive Persons and Relationship with Markers of Deteriorating Renal Function**, A. Mocroft (EuroSIDA in EuroCOORD)

*Thursday 17. October at 14.00-16:00/ Gold Hall*

**Infection Related and Unrelated Malignancies, HIV and the Aging Population**, L. Shepherd (EuroSIDA in EuroCOORD)

*Thursday 17. October at 14.00-16:00/Copper Hall*

**Organisation and Delivery of Healthcare for HIV/TB Coinfected Patients in Europe**, M. Mansfeld (TB:HIV Study in EuroCOORD)

*Friday 18. October at 14.00-16:00/Gold Hall*

**Best Poster discussion: Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons: results from the EuroSIDA cohort study**, J-P Viard, L Shepard, J-C Souberbielle, J-P Bastard, S Fella, J Capeau, J Reekie, P Reiss, A Blaxhult, M Bickel, C Leen, O Kirk, J D Lundgren, A Mocroft on behalf of EuroSIDA in EuroCOORD, BPD 1/2

*Thursday 17th October at 13.00-14:00 /Gold Hall*

#### **Posters:**

### **Do you have research ideas for EuroSIDA?**

Active involvement of clinicians in the scientific projects is strongly encouraged by the EuroSIDA Steering Committee. All EuroSIDA Investigators with research ideas, are very welcome to contact Amanda Mocroft at [a.mocroft@ucl.ac.uk](mailto:a.mocroft@ucl.ac.uk) and Ole Kirk at [oki@cphiv.dk](mailto:oki@cphiv.dk), to discuss possible project proposals.

### **Follow-up forms for dataset 38**

Deadline for follow-up forms for dataset 38 was 1 September. We kindly ask all centres to return all forms as soon as possible to prepare for dataset 39.

### **Reimbursement 2013**

Reimbursement is in process and all payments will be transferred in October as planned.

### **Update from EuroCoord**

Please find the latest from EuroCoord at: newsletter at [www.eurocoord.net](http://www.eurocoord.net)



**Development of thrombocytopenia and risk of AIDS and serious non-AIDS events in Europe**, AH Borges, JD Lundgren, O Kirk, A Ridolfo, C Katlama, F Antunes, A Grzeszczuk, A Blaxhult, VM Mitsura and A Mocroft on behalf of EuroSIDA in EuroCOORD, Poster No. PE 12/11

**Estimation of percentage of HIV-infected people with limited future drug options in a closed observational setting over the period 2007-2011 and beyond**, A Cozzi-Lepri, AN Phillips, R Paredes, E Jablonowska, E Florence, C Pedersen, T Staub, B Ledergerber, A Mocroft and J Lundgren for EuroSIDA in EuroCoord  
Poster No. PE9/12

**Is Stavudine (D4T) still being used in EuroSIDA despite its association with toxicity and a higher frequency of severe adverse events?**, D Grint, D Podlekareva, I Karpov, A Rakmanova, N Chentsova, J D Lundgren, A Mocroft, O Kirk for EuroSIDA in EuroCoord, Poster No. PE8/5

**Management of cardiovascular risk in HIV positive individuals in Europe**, M Shahmanesh, A Schultze, F Burns, O Kirk, J Lundgren, C Mussini, C Pedersen, S De Wit, G Kutsyna, and A Mocroft on behalf of EuroSIDA in EuroCoord, Poster No. PE15/18

**A Survey of ATRIPLA Use in Clinical Practice among Treatment-naïve HIV-positive Patients in Europe**  
O Kirk, P Reiss, A Rakhmanova, D Benhegyi, AN Phillips, S De Wit, M Ristola, JD Lundgren, J Garup, A Mocroft, for EuroSIDA in EuroCoord, Poster No. PE8/38

**Publications since May 2013**  
**Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.** H Kovari, CA Sabin, B Ledergerber, L Ryom, SW Worm, C Smith, A Phillips, P Reiss, E Fontas, K Petoumenos, S De Wit, P Morlat, JD Lundgren, R Weber.  
Clin Infect Dis. 2013 Mar;56(6):870-9.

**Severe bacterial non-AIDS infections in HIV-positive persons: incidence rates and risk factors.** OS Søgaaard, J Reekie, M Ristola, D Jevtovic, I Karpov, M Beniowski, S Servitskiy, P Domingo, P Reiss, A Mocroft, O Kirk for EuroSIDA in EuroCoord.  
J Infect. 2013 May;66(5):439-46.

**Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-related Death in HIV/Viral Hepatitis Coinfected Patients.** L Peters, A Mocroft, V Soriano, J Rockstroh, A. Rauch, A Karlsson, B Knysz, C Pradier, K Zilmer, JD Lundgren, for EuroSIDA in EuroCoord.  
PloS One. 2013 May 27;8(5):e64283. doi: 10.1371/journal.pone.0064283.

**Insurability of HIV positive people treated with antiretroviral therapy in Europe: Collaborative analysis of HIV cohort studies.** J Kaulitz-Bartz J, W Dam, MT May, B Ledergerber, U Widmer, AN Phillips, S Grabar, A Mocroft et al.  
AIDS. 2013 Jun 19;27(10):1641-1655.

**Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).** A Mocroft, JD Lundgren, M Sabin, A d'Arminio Monforte, N Brockmeyer, J Casabona, A Castagna, D Costagliola, F Dabis, S De Wit, G Fätkenheuer, H Furrer,

AM Johnson, O Kirk, for the Late Presenters Working Group, on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord.  
PLoS Med. 2013 10(9): e1001510.

**The incidence of AIDS defining illnesses (ADIs) at a current CD4 count > 200/mm<sup>3</sup> in the post combination antiretroviral therapy era.**

A Mocroft, HJ Furrer, J Miro, P Reiss, C Mussini, O Kirk et al. for COHERE in EuroCoord.  
Clin Inf Dis 2013 ;57(7):1038-1047

**In Press or E-pub, please see webpage:**

<http://www.cphiv.dk/EuroSIDA/Publications/InPress/tabid/512/Default.aspx>

**Total EuroSIDA publications as of September 2013: 189 + 7 in press or E-pub**

EuroSIDA Coordinating Centre: Copenhagen HIV Programme, Rigshospitalet, Copenhagen University Hospital and University of Copenhagen, Faculty of Health and Medical Sciences, Building 21.1, Blegdamsvej 3B, 2200 Copenhagen N, Denmark, Tel: +45 35 45 57 57, Fax: +45 35 45 57 58, e-mail: [eurosidea@cphiv.dk](mailto:eurosidea@cphiv.dk)  
website: <http://www.cphiv.dk>